• Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
Hamlet BioPharma
  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
Press enter to begin your search

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Newsletter

Press release

Presentation

CANCER

Read more

Infections

Read more

Tuberculosis

Read more

See all news →

Recent Posts Extra

  • Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer November 29, 2023
  • Kallelse till extra bolagsstämma i Hamlet BioPharma AB November 27, 2023
  • Hamlet BioPharma AB föreslår företrädesemission av B-aktier med möjlighet att säkra cirka 40MSEK. Cirka 13MSEK har tecknats i förhand via teckningsförbindelser. Tekniskt uppgår emissionen till 80MSEK November 27, 2023
  • Hamlet BioPharma publicerar årsredovisning 2022/2023 November 23, 2023
  • Q1 Interim report July – September 2023 November 17, 2023

About Hamlet Biopharma

hbp-logo

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet Biopharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive newsletters

© 2023 Hamlet BioPharma.

  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
  • Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

Swedish